Gide advises BioMérieux on acquisition of Chinese biomedical company Hybiome
Gide has advised BioMérieux, a world leader in the field of in vitro diagnostics, on its acquisition of a majority stake in Suzhou Hybiome Biomedical Engineering Co., Ltd.
As part of the deal, the French listed company (Euronext Paris: BIM) acquired 54% of the shares in Hybiome for a valuation of EUR 165 million, as well as additional assets such as distribution rights and existing installed base for EUR 25 million. It had already purchased a minority stake in the Suzhou-based company earlier this year in July, a transaction on which Gide also advised.